The new division — called Celmatix Biosciences — will focus on women's health indications with high unmet need including reproductive disorders and menopause.
The investment bank called Genomic Health a leader in diagnostic testing and said Invitae will benefit from growth trends in the genetic testing sector.
The firm said clinical services revenues fell during the quarter due to reduced insurance reimbursement payments and mix of testing in the prior year.
As part of the deal, which is worth at least $3 million for the first five years, Primerdesign will develop and supply 384-well plate molecular assay panels for Genesis.
The firm missed the Wall Street estimates on the top and bottom lines, and it lowered its EPS and adjusted EPS guidance for full-year 2018.
The firm said the decline in Q4 revenues was due to an account loss as well as lower insurance reimbursement and shifts away from high-value genetic testing.
The assets include significant genetic data related to women's diseases and degenerative disc disease, which Predictive will use to develop gene-based diagnostics.
The lab created active molecular identification tags to be able to track specimens themselves, rather than just their containers.
The company's life sciences segment had $1.08 billion in revenues, driven by strong performance of the preanalytical systems, diagnostic systems, and biosciences units.
The firm's 14 percent growth in molecular diagnostics sales was driven primarily by continued strength across its Aptima women's health products globally.
Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.
John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.
Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.
In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.